Future savings from specialty pharmacies will come at pharma companies' expense.
Thomas Baker
Advertisement
Articles by Thomas Baker
Advertisement
Latest Updated Articles
Specialty Therapies Lose Special StatusPublished: September 1st 2004 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
4
Roundup: Pharma Industry Raises Funding Aimed at Advancing the Development and Testing of Rare Disease Treatments
5
